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AbstrAct
Objective
To examine the validity and findings of studies that 
examine the accuracy of algorithm based smartphone 
applications (“apps”) to assess risk of skin cancer in 
suspicious skin lesions.
Design
Systematic review of diagnostic accuracy studies.
Data sOurces
Cochrane Central Register of Controlled Trials, 
MEDLINE, Embase, CINAHL, CPCI, Zetoc, Science 
Citation Index, and online trial registers (from 
database inception to 10 April 2019).
eligibility criteria fOr selecting stuDies
Studies of any design that evaluated algorithm based 
smartphone apps to assess images of skin lesions 
suspicious for skin cancer. Reference standards 
included histological diagnosis or follow-up, and 
expert recommendation for further investigation or 
intervention. Two authors independently extracted 
data and assessed validity using QUADAS-2 (Quality 
Assessment of Diagnostic Accuracy Studies 2 tool). 
Estimates of sensitivity and specificity were reported 
for each app.
results
Nine studies that evaluated six different identifiable 
smartphone apps were included. Six verified 
results by using histology or follow-up (n=725 
lesions), and three verified results by using expert 
recommendations (n=407 lesions). Studies were 
small and of poor methodological quality, with 
selective recruitment, high rates of unevaluable 
images, and differential verification. Lesion 
selection and image acquisition were performed 
by clinicians rather than smartphone users. Two CE 
(Conformit Europenne) marked apps are available 
for download. SkinScan was evaluated in a single 
study (n=15, five melanomas) with 0% sensitivity 
and 100% specificity for the detection of melanoma. 
SkinVision was evaluated in two studies (n=252, 61 
malignant or premalignant lesions) and achieved 
a sensitivity of 80% (95% confidence interval 63% 
to 92%) and a specificity of 78% (67% to 87%) for 
the detection of malignant or premalignant lesions. 
Accuracy of the SkinVision app verified against expert 
recommendations was poor (three studies).
cOnclusiOns
Current algorithm based smartphone apps cannot 
be relied on to detect all cases of melanoma or other 
skin cancers. Test performance is likely to be poorer 
than reported here when used in clinically relevant 
populations and by the intended users of the apps. 
The current regulatory process for awarding the CE 
marking for algorithm based apps does not provide 
adequate protection to the public.
systematic review registratiOn
PROSPERO CRD42016033595.
Introduction
Skin cancer is one of the most common cancers in the 
world, and the incidence is increasing.1 In 2003, the 
World Health Organization estimated that between two 
and three million skin cancers occur globally each year, 
80% of which are basal cell carcinoma, 16% cutaneous 
squamous cell carcinoma, and 4% melanoma (around 
130 000 cancers).2 By 2018, estimates had risen to 
287 723 new melanomas worldwide.1 Despite its 
lower incidence, the potential for melanoma to 
metastasise to other parts of the body means that it is 
responsible for up to 75% of skin cancer deaths.3 Five 
year survival can be as high as 91-95% for melanoma 
if it is identified early,4 which makes early detection 
and treatment key to improving survival. Cutaneous 
squamous cell carcinoma has a lower risk of metastatic 
spread.5 6 Cutaneous squamous cell carcinoma and 
basal cell carcinoma are locally invasive with better 
outcomes if treated at an early stage. Several diagnostic 
technologies are available to help general practitioners 
and dermatologists accurately identify melanomas by 
minimising delays in diagnosis.7 8 The success of these 
technologies is reliant on people with new or changing 
skin lesions seeking early advice from medical 
professionals. Effective interventions that guide people 
to seek appropriate medical assessment are required.
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WhAt Is AlreAdy knoWn on thIs topIc
Skin cancer is one of the most common cancers in the world, and the incidence 
is increasing
Algorithm based smartphone applications (“apps”) provide the user with an 
instant assessment of skin cancer risk and offer the potential for earlier detection 
and treatment, which could improve survival 
A Cochrane review of only two studies that tried to validate algorithm based skin 
apps suggested that there is a high chance of skin cancers being missed
WhAt thIs study Adds
This review identified nine eligible studies that evaluated apps for risk 
stratification of skin lesions, and showed variable and unreliable test accuracy 
for six different apps
Studies evaluated apps in selected groups of lesions, using images taken by 
experts rather than by app users, and many did not identify whether low risk 
lesions were truly benign
In a rapidly advancing field, quality of evidence is poor to support the use of 
these apps to assess skin cancer risk in adults with concerns about new or 
changing skin lesions
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Skin cancer smartphone applications (“apps”) 
provide a technological approach to assist people with 
suspicious lesions to decide whether they should seek 
further medical attention. With modern smartphones 
possessing the capability to capture high quality 
images, a wealth of “skin” apps have been developed 
with a range of uses.9 These skin apps can provide an 
information resource, assist in skin self examination, 
monitor skin conditions, and provide advice or 
guidance on whether to seek medical attention.10 
11 Between 2014 and 2017, 235 new dermatology 
smartphone apps were identified.12
Some skin cancer apps operate by forwarding 
images from the smartphone camera to an experienced 
professional for review, which is essentially image 
based teledermatology diagnosis. However, of 
increasing interest are smartphone apps that use 
inbuilt algorithms (or “artificial intelligence”) that 
catalogue and classify images of lesions into high 
or low risk for skin cancer (usually melanoma). 
These apps return an immediate risk assessment 
and subsequent recommendation to the user. Apps 
with inbuilt algorithms that make a medical claim 
are now classified as medical devices that require 
regulatory approval.13 14 These apps could be harmful 
if recommendations are erroneous, particularly if 
false reassurance leads to delays in people obtaining 
medical assessment. CE (Conformit Europenne) 
marking has been applied to allow distribution of two 
algorithm based apps in Europe,15 16 one of which 
is also available in Australia and New Zealand.16 
However, no apps currently have United States Food 
and Drug Administration (FDA) approval to allow 
their distribution in the US and Canada. Further, the 
American Federal Trade Commission has fined the 
marketers of two apps (MelApp17 and Mole Detective18) 
for “deceptively claiming the apps accurately analysed 
melanoma risk.”
These differences in regulatory approval and false 
evidence claims raise questions about the extent and 
validity of the evidence base that supports apps with 
inbuilt algorithms. A previous systematic review with a 
search date of December 2016 examined the accuracy 
of mobile health apps for multiple conditions. This 
review identified six studies that reported on the 
diagnosis of melanoma, but accuracy seems to have 
been overestimated because it included findings 
from both development and validation studies.9 In 
our review, we aim to report on the scope, findings, 
and validity of the evidence in studies that examine 
the accuracy of all apps that use inbuilt algorithms to 
identify skin cancer in users of smartphones.19
Methods
This review extends and updates our systematic review 
of smartphone apps19 (which was limited to diagnosis 
of melanoma). We conducted our review according 
to methods detailed in the Cochrane Handbook for 
Systematic Reviews of Diagnostic Test Accuracy20 
and report our findings according to the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) extension for diagnostic test 
accuracy studies statement recommendations.21
Data sources
We conducted literature searches for our original 
Cochrane review from inception of the databases to 
August 2016.19 For this review, we carried out an 
updated search for studies published between August 
2016 and 10 April 2019. The databases searched were 
the Cochrane Central Register of Controlled Trials, 
MEDLINE, Embase, CINAHL, CPCI, Zetoc, Science 
Citation Index, US National Institutes of Health 
Ongoing Trials Register, NIHR Clinical Research 
Network Portfolio Database, and the World Health 
Organization International Clinical Trials Registry 
Platform. Online supplementary appendix 1 presents 
the full search strategies. We did not apply any 
language restrictions. The reference lists of systematic 
reviews and included study reports were screened for 
additional relevant studies.
study selection
Two reviewers independently screened the titles and 
abstracts of all retrieved records, and subsequently 
all full text publications. Discrepancies were resolved 
by consensus or discussion with a third reviewer. 
Studies of any design that evaluated algorithm or 
“artificial intelligence” based smartphone apps that 
used photographs (that is, macroscopic images) of 
potentially malignant skin lesions were eligible for 
inclusion if they provided a cross tabulation of skin 
cancer risk against a reference standard diagnosis. 
Reference standards were either histological 
diagnosis with or without follow-up of presumed 
benign lesions (estimating diagnostic accuracy), 
or expert recommendation for further investigation 
or intervention (eg, excision, biopsy, or expert 
assessment). Studies that used a smartphone magni-
fier attachment were excluded on the basis that 
such attachments are relatively uncommon among 
smartphone users, and are more often used in high 
risk populations for lesion monitoring. Studies 
developing new apps were excluded unless a separate 
independent “test set” of images was used to evaluate 
the new approach. Conference abstracts were excluded 
unless associated full texts could be identified. Online 
supplementary appendix 2 presents a list of excluded 
studies with reasons for exclusion. We contacted 
the authors of eligible studies when they presented 
insufficient data to allow for the construction of 2×2 
contingency tables or for supporting information not 
reported in the publication.
Data collection, quality assessment, and analysis
Two authors independently extracted data by using a 
prespecified data extraction form and assessed study 
quality. For diagnostic accuracy, each study would 
ideally have prospectively recruited a representative 
sample of patients who used the app on their own 
smartphone device to evaluate lesions of concern. 
Verification of results (blinded to the apps’ findings), 
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to determine whether each lesion evaluated was skin 
cancer or not, would have been conducted by using 
histological assessment (if excised) or follow-up (if not 
excised). For verification with expert recommendations, 
all lesions assessed by the app would be reassessed 
in person by an expert dermatologist. Data would be 
reported for all lesions, including those for which the 
app failed to provide an assessment. These aspects 
of study quality were assessed using the Quality 
Assessment of Diagnostic Accuracy Studies 2 tool 
(QUADAS-222; online supplementary appendix 3). Any 
disagreements were resolved by consensus.
We plotted estimates of sensitivity and specificity 
from each study on coupled forest plots for each 
variation of each app. The app recommendations 
associated with the risk of melanoma for the different 
apps were tabulated (table 1). When apps reported 
three risk categories (high, moderate, low risk), we used 
the recommendations provided by each app to decide 
whether moderate risk results from the app should be 
combined with low or high risk results for the estimation 
of test accuracy. In cases of ambiguity, both options 
were pursued. Because of scarcity of data and poor 
quality of studies, we did not perform a meta-analysis. 
Forest plots were produced using RevMan 5.3 (Nordic 
Cochrane Centre). We present data on a per lesion basis.
Patient and public involvement
The protocol for the review19 25 was developed 
and written with input from two coauthors with 
lived experience of skin cancer to ensure that due 
consideration was given to the patient and public 
perspective.
results
study selection
The search identified 418 unique records of which 
64 were selected for full text assessment along with 
16 studies identified for the original review (see 
online supplementary fig 1 for full PRISMA flow 
diagram). We contacted corresponding authors for 
further information on three studies. Responses 
were received from two authors, and one provided 
additional relevant information. We excluded more 
than a third of studies (30/80, 37.5%) on the basis 
of the index test. Reasons for exclusion were because 
studies did not evaluate smartphones or smartphone 
apps (n=18); they were development studies without 
independent validation (n=6); they used magnifying 
attachments to the phone camera (n=3); they 
operated on a store and forward teledermatology 
basis (n=2); or they were used for lesion monitoring 
(n=1). Two studies26 27 duplicated data included in 
other studies.28 29 The supplementary figure and 
online supplementary appendix 2 document the 
other reasons for exclusion.
characteristics of included studies
Nine studies (9/80, 11.3%) met eligibility criteria.23 24 
28-34 Six studies (including 725 skin lesions) evaluated 
the diagnostic accuracy of smartphone apps for risk 
stratification of suspicious skin lesions by comparing 
app risk gradings with a histopathological reference 
standard diagnosis (some incorporated clinical expert 
face to face diagnosis for some lesions).23 28 31-34 Five 
of the six studies aimed to detect melanoma only, 
and one33 aimed to differentiate between malignant 
(including melanoma, basal cell carcinoma, and 
squamous cell carcinoma) or premalignant lesions 
and benign lesions. Three studies (with 407 lesions) 
verified the smartphone app recommendations against 
a reference standard of expert recommendations for 
further investigation or intervention (identification of a 
lesion as malignant or premalignant,30 histology 
required or not,29 or a face to face consultation required 
or not24).
table 1 | summary of recommendations for low, moderate, and high risk lesions by named algorithm based apps included in this review
app Platform; app availability low risk moderate risk High risk comparison
currently available apps
SkinScan*†‡ iOS; Europe (CE marked),  
Australia, and New Zealand
“Typical”; keep track “Atypical”; moderately  
suspicious—keep track
High; no specific action 
recommended
H v M/L 
H/M v L
SkinVision§ with or  
without questionnaire
iOS, Android; Europe  
(CE marked)
“Not much to worry about”; 
monitor for any changes
“Some chaotic growth”;  
consult a doctor
“Abnormal growth”;  
consult a doctor asap
H v M/L 
H/M v L
apps with uncertain availability (urls not accessible)
Dr Mole*¶ Android/Amazon; app last 
updated 2 August 2015**
No specific action  
recommended
Consult specialist Consult specialist  
immediately
H/M v L
SpotMole* Android; app last updated 30 
March 2016††
Okay; see a doctor if still 
concerned
— “Problematic”;  
consult doctor
H v L
apps withdrawn from market
MelApp* iOS, Android Low Medium High H v M/L 
H/M v L
Mole Detective* iOS, Android Monitor; no consultation 
needed
“Symptoms of melanoma”; monitor 
and schedule annual dermatology 
appointment
“Several symptoms of 
melanoma”; consult 
dermatologist
H v M/L 
H/M v L
CE=Conformit Europenne; H=high risk; L=low risk; M=moderate risk. 
*Risk recommendations as reported by Chadwick and colleagues23 (no specific actions were identified for MelApp). SkinScan video published 18 January 2013 (https://youtu.be/xyOdAJnIPqA); 
does not report risk recommendations.
‡The specific action recommended by the app for a high risk lesion could not be determined.
§SkinVision YouTube video published 17 August 2017 (https://youtu.be/DqrGkJj1eEE).
¶Ngoo and colleagues24 report results for Dr Mole as percentage of bar filled (continuous risk) and selects cut-off percentage of 72.5% (sensitivity=specificity).
**https://apkpure.com/doctor-mole-skin-cancer-app/com.revsoft.doctormole; https://www.amazon.com/Doctor-Mole/dp/B007P8GA36
††https://play.google.com/store/apps/details?id=com.spotmole&hl=en_GB
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Studies evaluated six different named apps. 
Table 1 summarises these apps according to current 
availability. Of the six, only SkinScan and SkinVision 
are currently available; MelApp and Mole Detective 
were withdrawn from the market after American 
Federal Trade Commission investigations17 18; and Dr 
Mole and Spotmole appear to be no longer available. 
Two studies assessed one31 and three34 apps without 
disclosing their names.
Table 2 and table 3 summarise the characteristics of 
the included studies. Sample sizes ranged from 1523 
to 199 lesions,30 with up to 45%30 of lesion images 
reported as unevaluable. After exclusions, the mean 
number of included lesions was 91 (median 108). 
Three studies reported between five30 and 1023 24 
attempts to obtain an adequate image for each lesion, 
and one study28 analysed a minimum of three images 
for each lesion. Two studies included any type of skin 
lesion,30 33 and all other studies restricted inclusion to 
pigmented or melanocytic lesions only.
assessment of the validity and applicability of the 
evidence using QuaDas-2
Only four studies28 31 33 34 recruited a consecutive 
sample of study participants or lesions. The lesion 
selection process was otherwise unclear29 30 32 or 
convenience sampling was used.23 24 One prospective 
study recruited patients from the general population 
who attended a national skin cancer day held at 
three university medical centres30; one recruited 
patients who attended follow-up screening28; and 
seven recruited only patients selected for excision of 
suspicious lesions or assessment of skin problems by 
dermatologists.23 24 29 31-34 Only two studies included 
skin lesions as selected by study participants (up to 
two for each participant)29 30; two did not report lesion 
selection31 32; and in five,23 24 28 33 34 the clinician 
performed lesion selection. Only two studies were 
rated to be at low risk of bias for patient selection, 
and in eight of the nine studies, the selection of skin 
lesions for assessment did not reflect the lesions that 
would be assessed in the population who might use the 
smartphone apps (fig 1).
We had high (eight of nine) or unclear (one of nine) 
concerns about the application of the index test. In 
seven studies24 28-33 researchers, rather than study 
participants, used the app to photograph lesions. Two 
studies used previously acquired images of excised 
lesions obtained from dermatology databases,23 34 
which raised concerns that the results of the studies 
were unlikely to be representative of real life use. Image 
quality was likely to be higher than in the real life 
setting for two reasons: archived images were chosen on 
the basis of image quality; or a clinician or researcher 
prospectively acquired images by using a standard 
protocol under optimised conditions and using a 
single smartphone camera rather than by participants 
using their own individual devices. Studies reduced 
the number of non-evaluable images by attempting 
up to 10 image submissions for each lesion. One study 
considered the results of a minimum of three images 
for each lesion in the final risk assessment.28
table 3 | characteristics of studies that reported accuracy of smartphone apps verified by expert recommendations for further investigation or 
intervention
study,  
country apps
no of 
patients, 
lesions inclusion criteria
exclusion  
criteria
Data  
collection
choice of 
lesions, 
image  
acquisition
reference standard, 
target condition
no of  
exclusions (%)
no of cancers/total 
analysed, %  
(final diagnoses)
Chung 
(2018),30 
Netherlands
SkinVision  
(version NR)
125, 199 Visitors of the  
National Skin  
Cancer Day  
(up to 2 lesions 
selected for  
assessment by 
attendees)
NR Prospective Patient, 
clinician
Expert assessment  
(appears to be face to 
face), malignant or  
premalignant v 
benign
Unevaluable  
images 90 (45%)*
9/109, 8.3% (final 
diagnoses NR; expert 
diagnoses: 6 BCC, 1 
BD, 1 AK, 1 angioma 
plus 54 BN, 7 atypical 
BN, 21 SK, 8 SL, 7 DF, 
3 other BN)
Nabil (2017),29 
Netherlands
SkinVision  
(version NR)
NR, 151 New patients  
referred by GP to  
the pigmented  
lesion clinic  
(up to 2 lesions  
selected for  
assessment by 
attendees)
NR Prospective Patient, 
clinician
Expert assessment  
in face to face  
consultation,  
histopathology  
warranted v no  
histopathology
No unevaluable  
images reported
8/151, 5.3% (final 
diagnoses NR; expert 
diagnoses obtained 
from author: 5 MM, 
3 BCC, 3 AK, 3 DF, 
17 DN, 86 BN, 3 
angioma, 4 SL, 2 blue 
naevus, 1 SN, 1 giant 
comedo)
Ngoo (2018),24 
Australia
SkinVision  
(version NR),  
SpotMole,  
Dr Mole
30, 57 Surgical list  
patients with  
pigmented  
lesions scheduled  
for excision,  
participants from 
naevus  
morphology study
Lesions on  
non-typical  
skin 
surfaces, 
poor image 
quality,  
keratinocyte  
lesions
Prospective Clinician, 
clinician
Expert assessment 
of dermoscopic and 
clinical images, lesion 
warrants in-person 
consultation v benign
Poor quality images 
excluded a priori 
4/38 (11%), plus 
3 participants with 
ineligible lesions and 
1 with no excision; 
unevaluable images: 
SkinVision iOS 8 
(14%), SkinVision 
Android 10 (18%)†
42/57, 73.7%  
(expert diagnoses NR;  
histology reported 
1 MiS)
AK=actinic keratosis; BCC=basal cell carcinoma; BD=Bowens disease; BN=benign naevi; DF=dermatofibroma; DN=dysplastic naevi; GP=general practitioner; MiS=melanoma in situ; 
MM=malignant “invasive” melanoma; NR=not reported; SK=seborrhoeic keratosis; SL=solar lentigo; SN=Spitz naevi.
*Up to five attempts for each lesion.
†Up to 10 attempts for each lesion.
RESEARCH
6 doi: 10.1136/bmj.m127 | BMJ 2020;368:m127 | the bmj
Most diagnostic accuracy studies (n=5) aimed 
to differentiate between melanomas and benign 
lesions23 28 31 32 34; one study33 included other types 
of skin cancer and premalignant lesions as the target 
condition. The risk of bias for the reference standard 
was low in only two studies.23 34 Five studies used 
expert diagnosis to confirm the final diagnosis for 
at least some lesions, with no confirmation by the 
preferred reference standard of histopathology or lesion 
follow-up.24 29 30 32 33 Additionally in five studies it was 
unclear whether the final diagnosis had been made 
without any knowledge of the app result.28 29 31 32 33
Exclusion of unevaluable images for which the 
app could not return a risk assessment might have 
systematically inflated the diagnostic performance of 
the tested apps in six of the nine papers.24 28 30 31 32 34 
Four studies reported exclusion criteria,23 24 28 34 
which included difficult to diagnose conditions; poor 
image quality; and unequivocal results obtained 
from the apps. For example, Maier and colleagues28 
assessed a minimum of three images for each lesion. 
They excluded lesions with images from the same 
lesion falling into high and low risk categories, and tie 
cases, when the three images from a single lesion are 
categorised at different risk levels (high, medium, and 
low risk).
study synthesis: sources of variability in test 
performance
All but one of the identifiable apps report lesion 
recommendations as high, moderate, or low risk 
(table 1); only SpotMole does not feature a moderate 
risk result. We were unable to identify the action 
recommended for a high risk result from SkinScan and 
MelApp, and have assumed that, as for other apps, 
users would (be recommended to) consult a doctor. 
For moderate risk lesions, two apps recommend lesion 
monitoring (SkinScan and Mole Detective) and two 
recommend consulting a doctor (SkinVision and Dr 
Mole), although with less urgency than implied for a 
high risk result.
Other sources of variability included varying defi-
nitions of the target condition (any malignant or 
premalignant lesion in one study,33 and melanoma only 
in five studies); different app versions (adaptations to 
improve the performance of apps for non-pigmented 
lesions and apps for different mobile phone platforms); 
consideration of results of a short user questionnaire; 
and mode of image upload (directly into the app v 
indirectly from the phone’s internal storage).
test performance of algorithm based skin cancer 
apps
Figure 2 presents the results of the two apps that are 
currently available on a per lesion basis. SkinScan 
was evaluated in a single study of only 15 lesions (five 
melanomas).23 Sensitivity was low regardless of whether 
moderate risk was combined with the low or high risk 
category (0% or 20% respectively), with corresponding 
specificities of 100% and 60% (fig 2). When only 
high risk results were considered as test positive, the 
original SkinVision app demonstrated a sensitivity 
of 73% (95% confidence interval 52% to 88%) in a 
study of pigmented lesions (n=144, 26 melanomas)28; 
however, sensitivity was only 26% (12% to 43%) when 
applied to pigmented and non-pigmented lesions 
(n=108, 35 malignant or premalignant lesions).33 The 
app only correctly picked up one of three melanomas 
as high risk.33 Corresponding specificities were 83% 
and 75% (fig 2). A later revision of the app to allow for 
non-pigmented lesions led to a 15 percentage point 
increase in sensitivity for the detection of melanoma 
when applied to the original pigmented lesion dataset 
(88%, 95% confidence interval 70% to 98%); however, 
High
High
High
Chadwick 201423 Low
Low
Low
Low
Low Low
Unclear Unclear
Unclear Unclear
High High
Patient
selection
Index
test
Reference
standard
Patient
selection
Index
test
Reference
standard
Flow and
timing
Risk of biasStudy
reference
Concerns about applicability
Dorairaj 201731
Verified by histology or specialist diagnosis
LowLow
High
High
Low
UnclearHighUnclear High High
Maier 201528
Robson 201232
Thissen 201733
Wolf 201334
Low UnclearHighUnclear High
Unclear
High
High
High
Chung 201830 Low High
Nabil 201729
Verified by expert recommendations for further investigation or intervention
Low High
Ngoo 201824 Low High
High
High
High
High
High
High
HighHigh High High High
Unclear
Unclear
High
Unclear HighHigh High High
High High High
High
fig 1 | Overview of risk of bias and applicability concerns of included studies
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specificity dropped by 3 percentage points (79%, 70% 
to 86%).33 Additionally, sensitivity for the detection 
of malignant or premalignant lesions increased by 45 
percentage points when applied to the pigmented and 
non-pigmented lesion dataset (71%, 54% to 85%), 
but specificity dropped by 19 percentage points (56%, 
44% to 68%).33 When participant responses to in-app 
questions about lesion characteristics and symptoms 
were included, sensitivity increased further to 80% 
(63% to 92%) and specificity to 78% (67% to 87%).33
When the interpretation of SkinVision was varied 
to consider high and moderate results from the app 
as test positive, sensitivity increased (between 17 and 
57 percentage points) but at a considerable cost to 
specificity (falling by 11-45 percentage points).33
Three studies assessed the SkinVision app.24 29 30 
The app was verified against expert recommendations 
for further investigation or intervention, presumably 
using the original version of the app.24 29 30 Agree-
ment between the app and the expert lesion 
assessment was poor and variable regardless of 
the threshold for test positivity applied (fig 2). 
When only high risk results were considered as test 
positive, between 25% (95% confidence interval 
3% to 65%)29 and 67% (30% to 93%)30 of lesions 
that the dermatologist considered to require further 
investigation were picked up by the app (with 
specificities of 90% and 61%, respectively). When 
high and moderate risk results were considered as 
test positive, sensitivities ranged from 57% to 78%, 
and specificities from 27% to 50% (fig 2).
Results from the five studies that reported data for 
apps with uncertain availability23 24 or withdrawn 
apps23 32 are if anything more variable. These variable 
results could partly be caused by smaller sample sizes, 
with either low sensitivities (25-50% for MelApp) or 
specificities (20-60% for Mole Detective, Dr Mole, and 
SpotMole). Online supplementary figure 2 presents 
the results for these studies and for the evaluations of 
unidentifiable apps.31 34
test failure
When apps failed to return a risk assessment, images 
were either excluded a priori from the studies,23 
excluded from analysis,24 28 30-32 34 or were not 
reported.29 Table 2, table 3, and figure 2 report the 
numbers excluded for each analysis because of test 
failure, which ranged from 3/188 (1.6%)34 to 90/199 
(45.2%).30 Only one study33 reported analysing all 
images to more closely mimic a real world setting.
High risk (consult a doctor) v moderate/low risk,
verified by histology with or without follow-up
0 0.2 0.4 0.8 1.00.6
Study Sensitivity
(95% CI)
Specificity
(95% CI)
TP/FP/FN/TN
Chadwick 2014 - SkinScan*
Maier 2015 - SkinVision* (original)
Thissen 2017 - SkinVision* (original)
Thissen 2017 - SkinVision* (rev+qu)
Thissen 2017 - SkinVision* (rev)
Thissen 2017 - SkinVision* (rev; Maier 2015 data)
1.00 (0.69 to 1.00)
0.83 (0.75 to 0.89)
0.75 (0.64 to 0.85)
0.78 (0.67 to 0.87)
0.56 (0.44 to 0.68)
0.79 (0.70 to 0.86)
Sensitivity
(95% CI)
0.00 (0.00 to 0.52)
0.73 (0.52 to 0.88)
0.26 (0.12 to 0.43)
0.80 (0.63 to 0.92)
0.71 (0.54 to 0.85)
0.88 (0.70 to 0.98)
0/0/5/10
19/20/7/98
9/18/26/55
28/16/7/57
25/32/10/41
23/25/3/93
High/moderate risk v low risk (no action),
verified by histology with or without follow-up
Chadwick 2014 - SkinScan*
Thissen 2017 - SkinVision* (original)
Thissen 2017 - SkinVision* (rev + qu)
Thissen 2017 - SkinVision* (rev)
0.60 (0.26 to 0.88)
0.30 (0.20 to 0.42)
0.19 (0.11 to 0.30)
0.67 (0.55 to 0.77)
0.20 (0.01 to 0.72)
0.83 (0.66 to 0.93)
0.97 (0.85 to 1.00)
0.97 (0.85 to 1.00)
1/4/4/6
29/51/6/22
34/59/1/14
34/27/1/54
All combinations of risk categories,
verified by expert recommendation for further investigation or intervention
Chung 2018 - SkinVision† - H v M/L
Chung 2018 - SkinVision† - H/M v L
Nabil 2017 - SkinVision† - H v M/L
Nabil 2017 - SkinVision† - H/M v L
Ngoo 2018a - SkinVision‡ - H/M v L
Ngoo 2018b - SkinVision* - H/M v L
0.61 (0.51 to 0.71)
0.32 (0.23 to 0.42)
0.90 (0.84 to 0.95)
0.42 (0.34 to 0.50)
0.27 (0.06 to 0.61)
0.50 (0.21 to 0.79)
0.67 (0.30 to 0.93)
0.78 (0.40 to 0.97)
0.25 (0.03 to 0.65)
0.75 (0.35 to 0.97)
0.72 (0.55 to 0.86)
0.57 (0.39 to 0.73)
6/39/3/61
7/68/2/32
2/14/6/129
6/83/2/60
26/8/10/3
21/6/16/6
0 0.2 0.4 0.8 1.00.6
Specificity
(95% CI)
fig 2 | forest plot estimates of sensitivity and specificity for studies of currently available algorithm based apps. Data are presented when only 
high risk results were considered as test positive, or when high and moderate risk results were considered as test positive. unevaluable images: 
chadwick 2014: excluded a priori; chung 2018: 90; maier 2015: 20; nabil 2017: not reported; ngoo 2018a: 10; ngoo 2018b: 8; thissen 2017: 0. 
fn=number of people with a false negative result; fP=number of people with a false positive result; H=high risk; l=low risk; m=moderate risk; 
rev=revised (version of the app); rev+qu=revised (version of the app) plus participant responses to questions about their skin lesion; tn=number of 
people with a true negative result; tP=number of people with a true positive result. *iOs; †mobile platform not reported; ‡android
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discussion
main findings
In this systematic review of algorithm based smart-
phone apps we found nine studies that evaluated six 
named apps for risk stratification of skin lesions, only 
two of which are known to be currently available for 
download in various parts of the world. Evaluations 
of apps with unknown availability and of those now 
withdrawn from the market because of “deceptive 
claims” were particularly small and with highly 
variable results. Our review shows small improvements 
over time in the diagnostic accuracy of one currently 
available app (SkinVision) and a stark lack of valid 
evidence for the other app (SkinScan). Identified 
studies of test accuracy have many weaknesses 
and do not provide adequate evidence to support 
implementation of current apps.
Despite the limitations of the evidence base, two 
algorithm based apps have obtained the CE marking 
and are currently being marketed with claims that they 
can “detect skin cancer at an early stage”15 or “track 
moles over time with the aim of catching melanoma 
at an earlier stage of the disease”.16 Under the EU 
Medical Device Directive35 smartphone apps are class 
1 devices. Manufacturers can apply CE marking to 
class 1 devices as long as they have shown compliance 
with the “essential requirements” as outlined in the 
Directive,35 and without necessarily being subject to 
independent inspection by notified bodies such as 
the Medicines and Healthcare products Regulatory 
Agency in the United Kingdom. Under the new Medical 
Device Regulations,36 37 which come into full force by 
May 2020, smartphone apps could be in higher device 
classes and will be subject to inspection by notified 
bodies. The FDA already has a stricter assessment 
process to evaluate mobile apps by taking a wider 
perspective of harm where “functionality could pose 
a risk to a patient’s safety if the mobile app were 
to not function as intended”.13 No skin cancer risk 
stratification smartphone app has received FDA 
approval to date.
Across the body of evidence presented, different apps 
recommended conflicting management advice for the 
same lesions.23 34 Additionally app recommendations 
commonly disagreed with histopathological results or 
clinical assessment, with some apps unable to identify 
any cases of melanoma.23
The SkinVision app produced the highest estimates 
of accuracy. Therefore, in a hypothetical population of 
1000 adults in which 3% have a melanoma, four of 30 
melanomas would not be picked up as high risk, and 
more than 200 people would be given false positive 
results (by using a sensitivity of 88% and a specificity 
of 79%, as observed by Thissen and colleagues33). 
However, performance is likely to be poor because 
studies were small and overall of poor methodological 
quality, and did not evaluate the apps as they would 
be used in practice by the people who would use 
them. Selective participant recruitment, inadequate 
reference standards, differential verification, and high 
rates of unevaluable images were particular problems.
challenges in evaluation studies
Firstly, smartphone apps are typically targeted at the 
general population with a relatively low prevalence 
of malignant lesions and a wide range of different 
skin conditions. Studies failed to recruit samples 
representative of this population. We found studies 
were based on images of suspicious skin lesions that 
had undergone excision or biopsy, and were further 
selected to only include conditions identified by the 
apps; for example, they excluded lesions with clinical 
and histological features similar to melanoma,34 or 
restricted inclusion to melanocytic lesions which 
are more likely to be recognised by apps.23 28 29 31 32 
Such fundamental differences in the spectrum of skin 
conditions compared with the general population 
means that poorer accuracy is likely to be observed 
in a real world setting.38 39 Study results are also not 
applicable to people with amelanotic melanomas 
(accounting for 2-8% of all melanomas),40 or to 
identify other more common forms of skin cancers 
such as cutaneous squamous cell carcinoma.
Secondly, image quality is a major concern for 
smartphone apps. Smartphone cameras are much 
more likely to be used in suboptimal conditions by 
the general population, which results in variable 
image quality. Even under controlled conditions, 
studies reported difficulties in obtaining clear images 
of large lesions, erosive surface of ulcerated tumours, 
mottled skin, lesions in skin folds, tanned skin, 
or multiple lesions in close approximation. These 
problems resulted in image exclusion and potential 
overestimation of diagnostic performance of skin 
cancer apps. The analysis of less than optimal images 
when used by smartphone users will further affect the 
ability of skin cancer apps to accurately differentiate 
between high risk and low risk lesions.
Thirdly, the lack of clarity in smartphone app 
recommendations could leave concerned users 
uncertain as to the best course of action. Reactions to 
a moderate risk result will probably depend on how 
risk averse people are, which will most likely result 
in variable decisions, with a risk of people failing to 
present to a specialist with a potentially malignant skin 
lesion. Therefore, predicting the true performance of 
the different apps in a real world setting is impossible 
without further research into behavioural responses in 
different groups of people with a range of lesion types.
Fourthly, algorithm based apps are constantly 
evolving. An evaluation of an app version and insights 
into its performance might not be applicable to the 
version available to users. Studies included in this 
review did not specify algorithm versions used for risk 
assessment and we do not know whether three studies 
of the SkinVision app29 30 33 considered the same app 
version or different versions.
Finally, the potential benefit of smartphone apps 
lies in their availability and use by people outside the 
healthcare system to evaluate lesions that cause them 
concern. However, all studies evaluated lesions or 
images selected and acquired by clinicians rather than 
lesions judged to be of concern to people using the apps. 
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Concern exists about the impact of false reassurances 
that algorithm based apps could give users with 
potentially malignant skin lesions, especially if they 
are dissuaded from seeking healthcare advice. These 
patients are not represented in the reported studies 
and thus we did not evaluate this risk. A considerable 
number of users will receive an inappropriate high 
risk result that could cause unnecessary worry and a 
burden on primary care and dermatology services.
Algorithms within current apps can be improved 
and might well reach performance levels suited 
for a screening role in the near future. However, 
manufacturers and researchers need to design 
studies that provide valid assessments of accuracy. A 
SkinVision study41 published after our search was 
conducted reported improved estimates of sensitivity 
for the detection of malignant or premalignant lesions 
for a new version of the app (95.1%, 95% confidence 
interval 91.9% to 97.3%) with similar specificity 
(78.3%, 77.3% to 79.3%). The study has used some 
images and data collected by real users of the app on 
their own phones, however the selection of malignant 
and benign lesions from several different sources is 
likely to have introduced bias. Two thirds (195/285) of 
the malignant or premalignant lesions originated from 
previous studies (including 40 melanomas from one 
study28 and eight melanomas plus 147 other malignant 
or premalignant lesions from another study33), with 
images taken by experts on patients referred to a 
clinic. Another 90 melanomas were identified from 
users of the app who had uploaded histology results 
after a high risk rating by a dermatologist and a high 
or moderate risk recommendation from the app (which 
will overestimate accuracy if more easily identifiable 
melanomas were included).41 Clinical assessment by 
a dermatologist of a single image submitted online 
with no histology, no in-person assessment, or follow-
up identified the 6000 apparently benign lesions 
included. Therefore, it is possible that this group might 
include some missed melanomas.
strengths and weaknesses of this review
The strengths of this review are that it used a 
comprehensive electronic literature search with 
stringent systematic review methods that included 
independent duplicate data extraction and quality 
assessment of studies, attempted contact with 
authors, and a clear analysis structure. We included 
an additional two studies29 30 that were not included 
in previous reviews. We also excluded between three42 
and five9 studies that reported the development 
(without independent validation) of new apps that 
were included in the other two reviews because such 
studies are likely to overestimate accuracy.
We included studies that verified app findings 
by using expert recommendations for investigation 
or intervention, in addition to studies that used 
histology with or without follow-up. Studies that used 
histology and follow-up are more reliable because 
the app assessments are evaluated against the true 
final diagnosis of study lesions; low sensitivities 
or specificities reflect the apps’ inability to identify 
melanomas or other skin cancers as high risk. Studies 
that verify findings against expert recommendations 
can only provide an idea of the level of agreement 
between the algorithm’s risk assessment and a 
dermatologist’s clinical management decision; agree-
ment between the two does not necessarily mean the 
risk assessment made was the correct one for the lesion 
concerned.
implications for practice
Despite the increasing availability of skin cancer apps, 
the lack of evidence and considerable limitations in 
the studies ultimately highlight concerns about the 
safety of algorithm based smartphone apps at present. 
The generalisability of study findings is of particular 
concern. Investment in algorithm based skin cancer 
apps is ongoing, with the company behind SkinVision 
announcing an investment of US$7.6m (£5.8m; 
€6.8m) in 2018.43 Subsequently, in March 2019,44 
this app was selected to join the UK NHS Innovation 
Accelerator as a possible new technology to support 
earlier diagnosis and prevention of cancer. Therefore, 
it is vital that healthcare professionals are aware of 
the current limitations in the technologies and their 
evaluations. Regulators need to become alert to the 
potential harm that poorly performing algorithm based 
diagnostic or risk stratification apps create.
implications for research
Future studies of algorithm based smartphone apps 
should be based on a clinically relevant population of 
smartphone users who might have concerns about their 
risk of skin cancer or who could have concerns about a 
new or changing skin lesion. Lesions that are referred 
for further assessment and those that are not must be 
included. A combined reference standard of histology 
and clinical follow-up of benign lesions would provide 
more reliable and more generalisable results. Complete 
data that include the failure rates caused by poor image 
quality must be reported. Any future research study 
should conform to reporting guidelines, including 
the updated Standards for Reporting of Diagnostic 
Accuracy guideline,45 and relevant considerations 
from the forthcoming artificial intelligence specific 
extension to the CONSORT (Consolidated Standards of 
Reporting Trials) statement.46
conclusion
Smartphone algorithm based apps for skin cancer 
all include disclaimers that the results should only 
be used as a guide and cannot replace healthcare 
advice. Therefore, these apps attempt to evade any 
responsibility for negative outcomes experienced 
by users. Nevertheless, our review found poor and 
variable performance of algorithm based smartphone 
apps, which indicates that these apps have not yet 
shown sufficient promise to recommend their use. 
The current CE marking assessment processes are 
inadequate for protecting the public against the 
risks created by using smartphone diagnostic or 
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risk stratification apps. Smartphones and dedicated 
skin cancer apps can have other roles; for example, 
assisting in skin self-examination, tracking the 
evolution of suspicious lesions in people more at risk 
of developing skin cancer,47 48 or when used for store 
and forward teledermatology.49 50 However, healthcare 
professionals who work in primary and secondary 
care need to be aware of the limitations of algorithm 
based apps to reliably identify melanomas, and should 
inform potential smartphone app users about these 
limitations.
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